General Information of Drug (ID: DM5NC39)

Drug Name
SAGE-324 Drug Info
Indication
Disease Entry ICD 11 Status REF
Essential tremor or related tremors 8A04.1 Phase 2 [1]
Parkinson disease 8A00.0 Phase 1 [2]
Cross-matching ID
TTD Drug ID
DM5NC39

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting GABA(A) receptor (GABAR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PH94B NS DMDC7OH Social anxiety disorder 6B04 Phase 3 [3]
OV101 DMA6LR3 Angelman syndrome LD90.0 Phase 3 [4]
Padsevonil DMRZ1F2 Epilepsy 8A60-8A68 Phase 2/3 [5]
BTD-001 DMS6ZA0 Narcolepsy 7A20 Phase 2 [6]
Evt201 DM8QXEY Sleep-wake disorder 7A00-7B2Z Phase 2 [7]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
GABA(A) receptor (GABAR) TTCI43M NOUNIPROTAC Modulator [2]

References

1 ClinicalTrials.gov (NCT04305275) A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor. U.S. National Institutes of Health.
2 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study. Front Pharmacol. 2021 Oct 8;12:757825.
5 Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models. J Pharmacol Exp Ther. 2020 Jan;372(1):11-20.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 The partial positive allosteric GABA(A) receptor modulator EVT 201 is efficacious and safe in the treatment of adult primary insomnia patients. Sleep Med. 2009 Sep;10(8):859-64.